Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2011 1
2012 1
2013 1
2014 3
2016 1
2017 3
2018 1
2019 1
2020 4
2021 2
2022 1
2023 3
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection.
Yuen MF, Lim SG, Plesniak R, Tsuji K, Janssen HLA, Pojoga C, Gadano A, Popescu CP, Stepanova T, Asselah T, Diaconescu G, Yim HJ, Heo J, Janczewska E, Wong A, Idriz N, Imamura M, Rizzardini G, Takaguchi K, Andreone P, Arbune M, Hou J, Park SJ, Vata A, Cremer J, Elston R, Lukić T, Quinn G, Maynard L, Kendrick S, Plein H, Campbell F, Paff M, Theodore D; B-Clear Study Group. Yuen MF, et al. N Engl J Med. 2022 Nov 24;387(21):1957-1968. doi: 10.1056/NEJMoa2210027. Epub 2022 Nov 8. N Engl J Med. 2022. PMID: 36346079 Clinical Trial.
HIV-Associated Kaposi's Sarcoma.
Hoffmann C, Sabranski M, Esser S. Hoffmann C, et al. Among authors: sabranski m. Oncol Res Treat. 2017;40(3):94-98. doi: 10.1159/000455971. Epub 2017 Feb 9. Oncol Res Treat. 2017. PMID: 28259888 Review.
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
Yuen MF, Asselah T, Jacobson IM, Brunetto MR, Janssen HLA, Takehara T, Hou JL, Kakuda TN, Lambrecht T, Beumont M, Kalmeijer R, Guinard-Azadian C, Mayer C, Jezorwski J, Verbinnen T, Lenz O, Shukla U, Biermer M; REEF-1 Study Group. Yuen MF, et al. Lancet Gastroenterol Hepatol. 2023 Sep;8(9):790-802. doi: 10.1016/S2468-1253(23)00148-6. Epub 2023 Jul 10. Lancet Gastroenterol Hepatol. 2023. PMID: 37442152 Clinical Trial.
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
AIDS-defining events among people living with HIV who have been under continuous antiretroviral therapy for more than one year, a German cohort study 1999-2018.
Pantke A, Kollan C, Gunsenheimer-Bartmeyer B, Jensen BO, Stephan C, Degen O, Schürmann D, Kurth T, Bremer V, Koppe U; HIV-1 Seroconverter Cohort and the ClinSurv HIV Cohort. Pantke A, et al. Infection. 2024 Apr;52(2):637-648. doi: 10.1007/s15010-024-02188-y. Epub 2024 Feb 21. Infection. 2024. PMID: 38381307 Free PMC article.
Recently acquired HCV infection in men who have sex with men in Germany in the direct-acting antivirals era and during the COVID-19 pandemic.
Ingiliz P, Lutz T, Schewe K, Baumgarten A, Krznaric I, Mauss S, Christensen S, Bickel M, Schmidt AJ, Sabranski M, He F, Jain S, Martin NK, Rockstroh JK, Boesecke C. Ingiliz P, et al. Among authors: sabranski m. HIV Med. 2024 Aug;25(8):967-975. doi: 10.1111/hiv.13651. Epub 2024 May 29. HIV Med. 2024. PMID: 38812289
Characterising HIV-Indicator conditions among two nationwide long-term cohorts of people living with HIV in Germany (1999-2023).
Krings A, Kollan C, Schmidt D, Gunsenheimer-Bartmeyer B, Valbert F, Neumann A, Wasem J, Behrens GMN, Bickel M, Boesecke C, Esser S, Dröge P, Ruhnke T, Koppe U; HIV-1 Seroconverter, ClinSurv-HIV study groups. Krings A, et al. Infection. 2024 Oct 30. doi: 10.1007/s15010-024-02419-2. Online ahead of print. Infection. 2024. PMID: 39476279
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E; NEAT 022 Study Group. Waters L, et al. Clin Infect Dis. 2023 Mar 4;76(5):861-870. doi: 10.1093/cid/ciac827. Clin Infect Dis. 2023. PMID: 36259527 Clinical Trial.
HIV-associated lung cancer: survival in an unselected cohort.
Hoffmann C, Kohrs F, Sabranski M, Wolf E, Jaeger H, Wyen C, Siehl J, Baumgarten A, Hensel M, Jessen A, Schaaf B, Vogel M, Bogner J, Horst HA, Stephan C. Hoffmann C, et al. Among authors: sabranski m. Scand J Infect Dis. 2013 Oct;45(10):766-72. doi: 10.3109/00365548.2013.810813. Epub 2013 Jul 23. Scand J Infect Dis. 2013. PMID: 23876190
23 results